Sonoma Pharmaceuticals, Inc.
SNOA
$2.79
$0.8040.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.56M | 3.58M | 3.39M | 3.44M | 3.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.56M | 3.58M | 3.39M | 3.44M | 3.14M |
| Cost of Revenue | 2.29M | 2.22M | 2.09M | 2.35M | 1.68M |
| Gross Profit | 1.27M | 1.36M | 1.31M | 1.09M | 1.46M |
| SG&A Expenses | 1.87M | 1.71M | 2.01M | 2.09M | 1.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.60M | 4.43M | 4.56M | 4.85M | 3.98M |
| Operating Income | -1.03M | -850.00K | -1.17M | -1.41M | -844.00K |
| Income Before Tax | -919.00K | -463.00K | -997.00K | -1.36M | -923.00K |
| Income Tax Expenses | 9.00K | 147.00K | 146.00K | -292.00K | -57.00K |
| Earnings from Continuing Operations | -928.00K | -610.00K | -1.14M | -1.07M | -866.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -928.00K | -610.00K | -1.14M | -1.07M | -866.00K |
| EBIT | -1.03M | -850.00K | -1.17M | -1.41M | -844.00K |
| EBITDA | -998.00K | -815.00K | -1.13M | -1.37M | -799.00K |
| EPS Basic | -0.63 | -0.59 | -1.34 | -1.39 | -1.59 |
| Normalized Basic EPS | -0.39 | -0.28 | -0.73 | -1.11 | -1.06 |
| EPS Diluted | -0.63 | -0.59 | -1.34 | -1.39 | -1.59 |
| Normalized Diluted EPS | -0.39 | -0.28 | -0.73 | -1.11 | -1.06 |
| Average Basic Shares Outstanding | 1.46M | 1.03M | 851.50K | 766.40K | 546.00K |
| Average Diluted Shares Outstanding | 1.46M | 1.03M | 851.50K | 766.40K | 546.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
